Ligand Pharmaceuticals Incorporatedの業績推移

損益計算書

	2018/12/31	2019/12/31	2020/12/31	2021/12/31	2022/12/31
Royalties	129	47	34	49	73
Captisol	29	31	110	164	104
Contract revenue
Total revenues
Cost of Captisol
Cost, Amortization
Research and development
General and administrative
Total operating costs and expenses
Gain from sale of Vernalis R&D
Income from continuing operations
Gain (Loss) on Investments
Interest income
Interest expense
Other income (expense), net
Total other expense, net
Income before income tax from continuing operations
Income tax benefit (expense)
Net income (loss) from continuing operations
Net loss from discontinued operations
Net income (loss):
Income (Loss) from Continuing Operations, Per Basic Share
Basic net income (loss) from discontinued operations (USD per share)
Basic net income (loss) per share (USD per share)
Income (Loss) from Continuing Operations, Per Diluted Share
Diluted net income (loss) from discontinued operations (USD per share)
Diluted net income (loss) per share (USD per share)